Coronavirus vaccine could be ready by October: Pfizer CEO claims
By MYBRANDBOOK
Pfizer’s CEO Albert Bourla said the company is conducting clinical trials in the US and Europe for the BNT162 vaccine programme to prevent Covid-19 in collaboration with German mRNA company BioNTech. Bourla said this while participating at a webinar by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) this week.
“If things go well and the stars are aligned, we will have enough evidence of safety and efficacy for us to feel comfortable, for the FDA (US Food and Drug Administration) to feel comfortable, and for the EMA (European Medicines Agency) to feel comfortable, to have a vaccine around the end of October,” Bourla was quoted as saying at the event by FierceBiotech. While GSK has joined forces with Sanofi, AstraZeneca is backing the vaccine being developed at the University of Oxford.
Pfizer is working with German firm BioNTech for several possible vaccines in Europe and the United States, said the report.
Besides, the report also quoted AstraZeneca boss who said that one or more vaccines could begin rolling out by the end of the year. AstraZeneca, in partnership with the University of Oxford, is working to come up with a vaccine and expects at least one could be ready by the end of 2020.
"The hope of many people is that we will have a vaccine, hopefully several, by the end of this year,” Pascal Soriot, head of AstraZeneca, was quoted in the report as saying. He, however, said “we are running against time".
The report also highlighted the warnings from experts saying the challenges could be "daunting" as the estimates show that about 15 million doses would be required to stop the pandemic.
According to the report, Soriot said that one of the challenges in coming up with a vaccine was declining transmission rates as it will be difficult "to properly conduct clinical vaccine trials in a natural setting".
According to the report, more than 100 labs across the world are working to develop a vaccine against the deadly virus. Of these, ten have made it to the clinical trial stage.
The deadly virus has killed over 358,000 people and infected more than five million worldwide so far.
Legal Battle Over IT Act Intensifies Amid Musk’s India Plans
The outcome of the legal dispute between X Corp and the Indian government c...
Wipro inks 10-year deal with Phoenix Group's ReAssure UK worth
The agreement, executed through Wipro and its 100% subsidiary,...
Centre announces that DPDP Rules nearing Finalisation by April
The government seeks to refine the rules for robust data protection, ensuri...
Home Ministry cracks down on PoS agents in digital arrest scam
Digital arrest scams are a growing cybercrime where victims are coerced or ...
ICONS OF INDIA : VIJAY SHEKHAR SHARMA
Vijay Shekhar Sharma is an Indian technology entrepreneur and multimil...
Icons Of India : PRATIVA MOHAPATRA
Prativa is a transformational leader with an incredible breadth of exp...
ICONS OF INDIA : RISHAD PREMJI
Rishad Premji is Executive Chairman of Wipro Limited, a $11.3 billion ...
GeM - Government e Marketplace
GeM is to facilitate the procurement of goods and services by various ...
IOCL - Indian Oil Corporation Ltd.
IOCL is India’s largest oil refining and marketing company ...
BEL - Bharat Electronics Limited
BEL is an Indian Government-owned aerospace and defence electronics co...
Indian Tech Talent Excelling The Tech World - JAYASHREE ULLAL, President and CEO - Arista Network
Jayshree V. Ullal is a British-American billionaire businesswoman, ser...
Indian Tech Talent Excelling The Tech World - Lal Karsanbhai, President & CEO, Emerson
Lal Karsanbhai, President and CEO of Emerson, assumed the leadership i...
Indian Tech Talent Excelling The Tech World - George Kurian, CEO, Netapp
George Kurian, the CEO of global data storage and management services ...